A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
A phase 1/2 trial of Fulvestrant in endometrial cancer and ovarian cancer, run by Terremoto Biosciences Inc., now recruiting.
Overview
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations is a phase 1/2 interventional study registered as NCT07109726 by Terremoto Biosciences Inc., with 205 participants planned, started 2025-09-23 and due to reach its primary completion in 2028-12-30. Interventions recorded: TER-2013, Fulvestrant injection. Conditions listed: Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- PersonJalid Sehouli
Shares Endometrial cancer, Cervical cancer, Ovarian cancer.
- PersonSébastien Armanet
Shares Endometrial cancer, Cervical cancer, Ovarian cancer.
- TrialA Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Ovarian cancer.
- TrialA Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Ovarian cancer.
- TrialBasket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Shares Fulvestrant, Endometrial cancer, Cervical cancer.
- PersonThomas Herzog
Shares Endometrial cancer, Cervical cancer, Ovarian cancer.
- TrialOpen-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Shares Fulvestrant, Ovarian cancer.
- Trial177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Shares Endometrial cancer, Cervical cancer, Ovarian cancer.